Biotage AB (publ)

to this webinar on our Q1 results. We will start with just a few slides on who we are, and then we will try to put a little more flavor to the executive summary that we have, and then Andrew will drive us through the financial update, and then hopefully lots of questions afterwards. So let's get rolling. I think you have seen this slide before, but it's always good to repeat what kind of a company are we? Because as we also have addressed in our Q1 report, not the least the CEO words that we have tried to simplify our strategies going forward, being more clear on that we are the global go-to separations company. And as you also know that we do have quite a lot of products that covers workflow solutions for our customers. That includes instrumentation, consumables and services. And as you can see in the middle of the slide that we are covering more or less all of the stages there is in a drug discovery. So we can facilitate most types of customers. And of course, to the right of the slide, you see all the modalities that we are having in our pipeline and our product portfolio. So I think we are pretty well equipped for also seeing some interesting growth going forward, which brings me to the next slide Just as an executive summary, as you all have seen this morning, we came out with a top line of 480 million SEC at 33% gross over last year with a very impressive gross margin of 63.1 and an uptake of 2.2% and that we are also pretty good in converting our sales to cash. As you can see that we have converted 171 million SEK and having an adjusted EBITDA of 126 million SEK. As I also wanted to allude to before we get to Andrew's There has been a tremendous growth in our recurring revenue that is now up at 72%. Some of you know that in the old days we were fighting to get to this percent and we have now moved from 67% out of the 2023 and now are 72%. And of course that has to do with the Estrella business that has grown with 78% over the last Q1 in 23. And as you also can see that now, our advanced therapeutics and biologics is now covering 30% of our business. So a very, very, very good going forward. There's one caveat that we are not happy with. also mentioned in the report, that was that we didn't succeed in getting the co-biotypes to a zero level or, as we said last time, a small increase. And you also know the reason. And in a positive way, we say there is a tremendous demand in the peptide business. And we were not able to fulfill that demand. Have we had the opportunity to do that? we would have had a very good single digit growth even into the core business.

We're working on it.

We are increasing the capacity going forward, and we are still seeing a tremendous growth in the peptide area. We are continuing to invest both in manufacturing facilities, but also in our R&D capabilities around the globe. So with that, I think I have, there's one slide more, which I want to just allude to, just to give you a flavor of that. It's not just our current business. We are also launching new products and you can see the Furobeats. And one of the things we are also constantly having in our mindset is that we need to continue to be Developing products that can be sustainable. And that we are trying to take out. Let's say if all the solvents we can and it goes for both both sides of the slides and that we also bringing more products into the PFAS area going forward and hopefully we will see slides also in the next. that are also having some instrumentation out on the field as new products. And by that, I hand over the word to Andrew.